NCT06919523View on ClinicalTrials.gov

Clinical Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patients With Refractory Cirrhotic Ascites

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

April 15, 2025

Primary Completion Date

August 15, 2025

Study Completion Date

September 15, 2025

Conditions
Refractory Ascites
Interventions
DRUG

Dapagliflozin 5mg

Dapagliflozin 5m orally once daily for 3 months plus standard care (diuretics and Large volume paracentesis)

DRUG

Standard care treatment

Diuretics and Large volume paracentesis as indicated

All Listed Sponsors
lead

Mansoura University

OTHER